Skip to main content
Clinical Trials/NCT02975908
NCT02975908
Unknown
Not Applicable

A Realworld Study of Acute Respiratory Distress Syndrome in China

China-Japan Friendship Hospital1 site in 1 country400 target enrollmentAugust 2015

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Acute Respiratory Distress Syndrome
Sponsor
China-Japan Friendship Hospital
Enrollment
400
Locations
1
Primary Endpoint
Mortality
Last Updated
9 years ago

Overview

Brief Summary

ARDS is a critical respiratory disease caused by endogenous and exogenous factors. The mortality of ARDS varies from 30 to 70%. In 2012, a new international diagnostic criterion has been put forward. Yet, its feasibility, reliability and validity need to be tested. Meanwhile, the correlation of different severity and prognosis remains unclear. As so far, the epidemiological information about ARDS in China is lacking.

Investigators plan to conduct a multi-center observational study(real-life study) to investigate the risk factors, morbidity, management and prognosis of ARDS in China, in order to facilitate standardization of diagnosis and management of ARDS and provide basic data and idea for further clinical intervention studies.

Registry
clinicaltrials.gov
Start Date
August 2015
End Date
February 2019
Last Updated
9 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
China-Japan Friendship Hospital
Responsible Party
Principal Investigator
Principal Investigator

Chen Wang

professor

China-Japan Friendship Hospital

Eligibility Criteria

Inclusion Criteria

  • ≥18 years of age; hospitalized patients with main diagnosis as ARDS.

Exclusion Criteria

  • \<18 years of age
  • Patients or their families refused to participate in the study
  • Patients diagnosed as COPD, pulmonary fibrosis or bronchiectasis

Outcomes

Primary Outcomes

Mortality

Time Frame: 28days

the 28days mortality after the diagnosis of ARDS

Secondary Outcomes

  • Incidence of ARDS(2 years)
  • Number of patients with high risk factors(1 week)
  • Length of ICU stay(90 days)
  • Ventilation free days(28 days)
  • Number of patients using adjuvant drugs(28 days)
  • Number of patients with impaired lung function(90 days, 1 year)
  • Severity of patients(2 years)
  • Number of patients with conventional respiratory support techniques(28 days)
  • Adverse events related to treatment(90 days)
  • Number of patients with unconventional respiratory support techniques(28 days)
  • Number of patients with abnormal lung CT(90 days, 1 year)

Study Sites (1)

Loading locations...

Similar Trials